Windward Bio closes $251.2M IPO and private placement, with underwriters' option exercised in full
Swiss clinical-stage biotech Windward Bio Group AG closed its Nasdaq IPO of 11,838,234 common shares at $17.00 each. The total includes the underwriters' full option of 1,544,117 shares. Gross proceeds, including a concurrent private placement, were about $251.2 million. Shares began trading on the Nasdaq Global Select Market as WWB on November 13, 2026. Windward is developing ultra-long-acting antibodies for respiratory and dermatologic diseases.
16 Nov 2026 · Windward Bio Group AG · Company news
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
More FinancingAll →
Financing
Kyntra Bio halts FG-3246 prostate cancer work, cuts royalty-financing cap and plans roxadustat MDS Phase 3
16 Nov 2026 · Kyntra Bio, Inc. KYNB · Company news
Financing
NervGen Pharma reports C$80.1M cash at Q3 2026 after May public offering; nine-month net income of C$2.5M
16 Nov 2026 · Nervgen Pharma Corp. NGEN · Company news
Financing
Hydrofarm posts Q3 2026 sales drop to $14.5M and wipes out $109M term loan in October recapitalization
16 Nov 2026 · Hydrofarm Holdings Group, Inc. HYFM · Company news
Financing
AMC Robotics posts Q3 2026 net loss of $2.02M on lower revenue and one-time financing costs
16 Nov 2026 · AMC Robotics Corp AMCI · Company news
Financing
Grande Group signs $40M ordinary share purchase facility with White Lion Capital
16 Nov 2026 · Grande Group Ltd/HK GRAN · Company news
Financing
Akebia secures up to $140M Symbiotic Capital term loan, repays $55M BlackRock facility
16 Nov 2026 · Akebia Therapeutics, Inc. AKBA · Company news